Perspectives towards predictive testing in Huntington disease

S. M. Nagaraja, Sanjeev Jain*, Uday B. Muthane

Departments of Neurology and *Psychiatry, National Institute of Mental Health and Neurosciences, Hosur Road, Bangalore - 560 029, India

Objective: Genetic counseling for individuals undergoing presymptomatic testing is lacking in India although testing is easily available. This has an impact on family members of Huntington’s disease (HD), an autosomal dominant disease, wherein the age at onset of symptoms varies.

Aim: We examine if attitudes differ towards presymptomatic testing for HD amongst HD family members, physicians and laypersons. Materials and Methods: A modified questionnaire enquiring about opinions on various personal, family, social and future health care with regards to presymptomatic testing of HD was designed. A physician explained briefly about HD and presymptomatic testing of HD and recorded responses of unaffected family members of HD (n=25) and laypersons (n=50). Medical doctors (n=50) answered the questionnaire based on their knowledge of HD.

Results: HD family members, Medical doctors and laypersons were similar in their opinion to undergo the testing. Majority (60%) of HD family members did not wish to communicate test results with their friends when compared to the other two groups. Medical doctors and HD family members were more concerned about certainty of developing disease when the test results are positive. Majority (80%) of Medical doctors and less than half in the other groups felt that their decision to have a child would strongly depend on test results. Large proportion (80%) of HD family members did not wish to report their test results to their employers.

Conclusions: Individuals with knowledge about HD and the test differ in their decision of sharing test results and reproductive choices.

Key words: Attitudes, genetic counseling, Huntington’s disease, presymptomatic testing

Huntington’s disease (HD) is an autosomal dominant progressive neurodegenerative disease, where pre-symptomatic genetic testing is available for over a decade. HD has an unpredictable onset and no treatment for either cure or delaying its progression. Presymptomatic testing is most frequently used in late onset autosomal dominant disorders such as Huntington’s disease (HD). Presymptomatic testing is primarily carried out in healthy or asymptomatic individuals to provide information about that individual’s future health, with respect to specific inherited diseases. A positive test result may indicate that the individual has a high likelihood of developing the disorder or of excluding it.[3]

A positive test for the defective gene has a good accuracy of predicting if an individual is at risk to develop the disease. The unpredictable age at onset in individuals with positive genetic tests for HD poses tremendous concerns. The at-risk population has many questions and fears in their minds about healthcare, psychological and social support from colleagues and their family.[2,4] It is thus essential to understand concerns of family members’ at-risk for HD and intraspect so that medical personnel, friends and family could address them adequately.

Supportive family bonds and religious values have often guided societal attitudes towards illness. This is particularly true of non-communicable diseases and is believed to contribute, for example, to the relatively better social outcome of schizophrenia.[11] Modern healthcare is available in India but delivery to patients, especially those with chronic disease, is not uniform. The economic burden of long term care of chronic disease like HD, as in Parkinson’s disease, schizophrenia is significant.[3]

In the western world where presymptomatic testing is widely available, guidelines for predictive testing for HD have been collaboratively developed by family members and health professionals and is used to advice about predictive testing for HD.[6,7] Approximately 500 individual tests are requested across UK, but these are handled with explicit counseling protocols in place.[9] Attitudes to testing vary, e.g., in Italy, where more than half who enlist in the program withdraw from testing, “most frequently due to a more realistic evaluation of all possible consequences of test results, after psychological counseling.”[9] In India, clinicians would need to be extremely sensitive while offering these tests due to widely differing educational levels, cultural and
social beliefs to these issues. We faced many such issues when we began researching into the genetics of HD and in the absence of any formal guidelines decided to evaluate attitudes towards the testing to help us develop guidelines in the future.

We thus conducted this study across a diverse sample to understand the opinions of relatives of HD probands towards the disease, impact of presymptomatic testing and implications of testing positive. We compared their opinions to those of medical doctors and the lay public who have no direct knowledge of this illness.

Materials and Methods

Setting

The study was carried out at the National Institute of Mental Health and Neurosciences, Bangalore, India, a large tertiary referral and research center for psychiatric and neurological disorders.

Subjects

We compared three groups of individuals, the first group consisted of 25 unaffected family members (spouse, children and first degree family members) of clinically and genetically confirmed HD probands (n=25), the second group were medical doctors’ (n=50) and the third group were laypersons randomly selected as ‘controls’ (n=50) from within the city of Bangalore. A brief written description of HD explaining its genetic nature, clinical features and problems of the disease was given and later explained by a single medical doctor (S.N.) All the participants, who consented to take part in the study were individually administered the modified questionnaire and all clarifications were answered by the research staff during the interview. The questionnaire is in English and was translated to their language, for ease of explanation, wherever it was required. Subjects were requested to answer questions under the assumption that they were at future risk of developing HD. Individuals with less than 10 years of formal school education were considered uneducated.

Questionnaire

The instrument contains 30 questions derived from other earlier studies inquiring about personal, family and social issues, as well as future health care. The questionnaire were modified with appropriate choices relevant to the socio-cultural situation.

Statistical analysis

The data was analysed using SPSS version 11 for windows. The mean and standard deviation for age was calculated. The percentage of individual who answered positive was calculated.

Results

Family members of HD probands were slightly older than the other two groups but were matched for sex and education profile (Table 1). Similar number of HD family members and doctors (60 and 66% respectively) would like to undergo genetic testing. A higher number (78%) of controls wanted to be tested for HD. Most HD family members (60%) did not wish to communicate test results to others. On the contrary, a higher number of doctors and controls wanted to communicate test results to others. HD family members felt that these results were important to their family as compared to controls (34%). Attitudes towards sharing the results were equivocal. HD family members often did not wish to share knowledge of their genetic status (60%) while similar

<table>
<thead>
<tr>
<th>Subjects (N)</th>
<th>Age (yrs) mean (SD)</th>
<th>M/F</th>
<th>Married/single</th>
<th>Education &gt;10 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huntington’s disease relatives (25)</td>
<td>48 ± 14</td>
<td>16/9</td>
<td>18/7 (2:1)</td>
<td>96%</td>
</tr>
<tr>
<td>Doctors (50)</td>
<td>30 ± 9</td>
<td>38/12</td>
<td>18/32 (1:1.8)</td>
<td>100%</td>
</tr>
<tr>
<td>Controls (50)</td>
<td>33 ± 12</td>
<td>24/26</td>
<td>21/29 (1:1.4)</td>
<td>100%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Questions</th>
<th>Opinion</th>
<th>HDF (%)</th>
<th>Doctors (%)</th>
<th>Laypersons (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Given all this information about the predictive test, would I like to undergo the test</td>
<td>Yes</td>
<td>60</td>
<td>66</td>
<td>78</td>
</tr>
<tr>
<td>Should I share this information about the predictive test and its results with others</td>
<td>No</td>
<td>60</td>
<td>40</td>
<td>40</td>
</tr>
<tr>
<td>The test results are important for</td>
<td>Family members/and friends</td>
<td>88</td>
<td>52</td>
<td>34</td>
</tr>
<tr>
<td>How important is certainty of getting the disease in my life, if my test results are positive</td>
<td>Very Important</td>
<td>64</td>
<td>70</td>
<td>52</td>
</tr>
<tr>
<td>I should discuss my risk about the disease with</td>
<td>Spouse</td>
<td>20</td>
<td>46</td>
<td>12</td>
</tr>
<tr>
<td>Can I talk openly to my partner about my anxiety concerning at risk status?</td>
<td>I can</td>
<td>64</td>
<td>76</td>
<td>66</td>
</tr>
<tr>
<td>How would the positive test results influence my decision about having children since the disease is familial</td>
<td>Influences</td>
<td>44</td>
<td>80</td>
<td>44</td>
</tr>
<tr>
<td>I should report a positive result to my employers</td>
<td>Disagree</td>
<td>80</td>
<td>48</td>
<td>20</td>
</tr>
<tr>
<td>Will the test results influence the decisions, which I have to take in my future life?</td>
<td>Influences</td>
<td>56</td>
<td>50</td>
<td>28</td>
</tr>
<tr>
<td>How will I cope with a positive test results</td>
<td>Manage to cope</td>
<td>80</td>
<td>78</td>
<td>88</td>
</tr>
<tr>
<td>Will the negative test results help me in becoming a better father/mother?</td>
<td>Yes</td>
<td>72</td>
<td>38</td>
<td>54</td>
</tr>
<tr>
<td>In your opinion, should this illness be covered by insurance or health care?</td>
<td>Yes</td>
<td>100</td>
<td>88</td>
<td>90</td>
</tr>
</tbody>
</table>

HDF = HD Family members
proportion of doctors and controls wanted to share with friends. Doctors (70%) were most concerned about the certainty of becoming ill after test results were known. Less than half of all groups would discuss results with a spouse (controls: 12%, HD at-risk: 20%; and doctors: 46%), but in contrast, they would not discuss their anxieties about the test with them. A large proportion of the doctors (80%) confirmed that the result would affect their decision to have children, while less than half of the other two groups would. Majority of HD at risk (80%) were unwilling to inform test results to employers while only 20% of controls felt so [Table 2]. All family members felt that access to organized care, after testing, was imperative, as did a large proportion of the others.

Discussion

Our survey highlights considerable ambiguities in attitudes of various groups towards testing. Individuals having a greater knowledge of the disease (family members, doctors) were more circumspect in handling genetic information. Medical personnel were most likely to change reproductive decisions and were concerned about the certainty of getting the disease. This probably reflects their greater understanding of the disease. Family members were obviously anxious about their status and were the only group that had difficulty coping with a positive or negative result. Attitudes towards a positive result were expectedly less enthusiastic, but most felt that a negative result would make them become a better parent. Normal controls frequently wanted to request tests but were least likely to share results with family members and did not anticipate that test results will alter their future decisions. They felt the least need to discuss with their spouse, but did not mind letting their employers know. We feel that these responses were different, as the laypersons, unlike the doctors and family members, had no definite idea about the nature of the disease or of genetic testing. In summary, even the lay public, having more than 10 years of formal education, show poor understanding of the illness or test results due to lack of disease information and its genetic implications.

These observations highlight the ambiguous relationship of individuals to predictive testing. Increased understanding of the scientific and clinical issues did not translate into a greater acceptance of the technology. The social responses were suggestive of a greater desire for privacy and autonomy, while at the same time expressing a need for long term care. These needs were most strongly expressed by those having a first hand knowledge of the disease and least by the laypersons.

Most guidelines suggest psychological support or a psychiatric referral to handle emotional consequences of a positive test. These guidelines also suggest the need for frequent re-contact to provide updates on treatment or other emergent issues. This was also observed in our sample, as most individuals were keen to know availability of preventive measures or newer treatments and methods to prevent passing the illness to their future generation. Implicitly, this requires life-long contact with a care service after an individual is tested positive and has a pre-symptomatic status. Issues of individual autonomy, decision-making and availability and affordability of such services need to be addressed in the Indian context as these tests become available. Several family members in our sample had directly experienced difficulties in obtaining reliable care. Many clinical service providers feel it their moral and ethical obligation to maintain long-term contact with individuals who have been tested. However, the legal status of this, as well as the logistics, is a source of worry. There has been a trend towards direct marketing of genetic tests, but their use in India as with female foeticide following sex-determination is not encouraging. It is advisable that individuals are protected from ‘inappropriate advertising and marketing’ of genetic tests of late onset disorders. It is observed that geneticists are less likely to consider testing than non-geneticist physicians. Services for continued care do not exist for the disabled or for chronic non-infective diseases in India. Advances in genomics suggest that these tests may soon be available for common multifactorial diseases like Alzheimer’s and Parkinson’s disease and psychoses. The knowledge of genetic disease status raises new ethical and moral obligations, in addition to impacting on employment and other social roles. These raise important clinical and ethical issues that have rarely been explored in the south Asian context.

Market forces and the aura of ‘genetics’ often neglect the warning that applying scientific advances to health care does not automatically benefit. The huge lag between diagnoses and available treatment and the absence of any counseling services, suggest the need to establish counseling services and provisions for long term care.

Our study had some limitations as the questionnaire was modified but was not standardized in our population. The questionnaire was in English and every effort was made to adequately communicate the intent of the questions by verbally translating and explaining these into the language the individuals understood by the same person.

Issues of autonomy need to be addressed not only within the doctor-patient relationship, but also the individual’s social network. Legal issues about the right to information and disclosure are essential. Most importantly, long term contact and care is crucial. Our study highlights the urgent need for providing genetic tests as part of a comprehensive health care service rather than for a mere diagnostic use and for developing guidelines and policies for handling the complex issues that will be raised by genetic technologies.

Acknowledgements

We thank Dr. G. Gururaj, Prof. of Epidemiology and NIMHANS for his valuable comments on the questionnaire. We are grateful to the family members of Huntington Disease patients, our medical colleagues and other members of the public who took time to answer the questionnaire. Support of the ICMR is acknowledged to SJ.
Nagaraja SM, et al.: Huntington’s disease and predictive testing

References

4. Hopper K, Wandelting J. Revisiting the developed versus developing country distinction in course and outcome in schizophrenia: Results from Los, the who collaborative followup project. International study of Schizophrenia. Schizophr Bull 2000;26:835-46.

Accepted on 09-10-2006

Source of Support: ICMR. Conflict of Interest: None declared.